secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2021-11-12T23:59:59+00:00
Accession:  0001193125-21-327268
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea reports Q3 net loss $28.2M; plans Phase 3 MORNINGSKY amendment with new primary endpoint
--------------------------------------------------------------------------------

- Net loss $28.2M for Q3 2021 vs $17.6M loss in Q3 2020; collaboration revenue $32.8M from Roche license.
- Cash and equivalents $839.7M as of Sept 30, 2021, down from $850.1M at Dec 31, 2020.
- Phase 3 MORNINGSKY amendment: primary endpoint to hospitalization/death; focus on unvaccinated high-risk; dose increased to 1,100 mg BID; data H2 2022.
- New infectious virus data from Phase 2 MOONSONG show rapid viral load reduction (-0.5 log10) with AT-527 1,100 mg BID vs placebo at Day 3 in overall population.
- In vitro data show AT-511 (free base of AT-527) maintains potency against variants including Delta.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312521327268/0001193125-21-327268-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312521327268/d249281d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-327268

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer